Rani Therapeutics Gears Up for Important Investor Conferences in September
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) is preparing to take part in two major investor conferences this September. These events offer an excellent opportunity for Rani to highlight its innovative biotherapeutics and connect with potential investors.
Upcoming Conferences
The first key event is the H.C. Wainwright 26th Annual Global Investment Conference, taking place on September 10, 2024, at the renowned Lotte New York Palace Hotel. During this conference, Chief Executive Officer Talat Imran will present, followed by one-on-one meetings with investors. This event is a valuable chance to gain insights into Rani’s unique methodologies and future plans.
H.C. Wainwright Conference Details
At the H.C. Wainwright conference, attendees will discover Rani's groundbreaking solutions aimed at transforming traditional drug delivery methods. The event will kick off at 4:30 pm E.T. and will include presentations that elaborate on Rani’s current projects and innovations in the biotherapeutics sector.
More About the 2024 Cantor Global Healthcare Conference
In addition to the H.C. Wainwright conference, Rani will also participate in the 2024 Cantor Global Healthcare Conference on September 18, 2024, at the InterContinental Barclay Hotel in New York. Once again, Talat Imran will represent Rani, engaging in a fireside chat along with one-on-one investor discussions. The fireside chat is set to begin at 11:30 am E.T., providing an excellent opportunity for in-depth conversations about Rani’s progress and the future of bio-delivery technology.
Cantor Conference Focus
This conference will emphasize Rani's dedication to improving drug bioavailability through its innovative RaniPill® capsule technology. Attendees will gain insights into the extensive research aimed at enabling oral delivery of biologics, which could greatly enhance patient experiences and treatment options.
About Rani Therapeutics
Rani Therapeutics is a leader in the biotherapeutics field, pioneering oral delivery methods for medications that typically require injections. Its flagship product, the RaniPill® capsule, represents a state-of-the-art delivery system designed to offer a more patient-friendly alternative to traditional injection-based therapies. The company’s research encompasses various preclinical and clinical studies that demonstrate the safety, tolerability, and bioavailability of this innovative capsule technology.
Research and Development Focus
With a strong commitment to research and development, Rani Therapeutics aims to transform patient care by facilitating easier and more effective treatment regimens. The RaniPill® capsule has the potential to make biologics more accessible and manageable, thereby improving adherence to treatment and ultimately enhancing patient outcomes.
Investor and Media Contact
For inquiries related to investor relations, please contact us via email at investors@ranitherapeutics.com. For media inquiries, reach out to media@ranitherapeutics.com.
Frequently Asked Questions
What is Rani Therapeutics known for?
Rani Therapeutics specializes in developing innovative oral delivery systems for biologics and drugs, particularly through its RaniPill® capsule technology.
When are the upcoming investor conferences?
The upcoming investor conferences for Rani Therapeutics are scheduled for September 10 and September 18, 2024.
Who will represent Rani Therapeutics at these events?
Talat Imran, the Chief Executive Officer, will represent Rani Therapeutics at both conferences.
What is the RaniPill® capsule?
The RaniPill® capsule is a proprietary oral dosing technology designed to replace traditional injection methods for biologics and drugs.
How can I access the webcasts of the conferences?
Interested individuals can access the live webcasts by visiting the “Events” section of the Rani Therapeutics website after registering.
